Year-End Sale is Live! Find Exclusive Prices on the Best Selling Pharma & MedTech Reports. Check Now!
Aug 23, 2019
The drug Imfinzi (durvalumab) has failed to come up as an effective treatment option for treating non-small cell lung cancer (NSCLC). The result of the NEPTUNE study was not much of a promising one and has been disclosed completely. The Pharma giant, AstraZeneca, has announced the incompetence of its lead candidate...
Read More...
Roche’s HER2-Positive Breast Cancer Treatment Franchise
Aug 13, 2024
Transforming Multiple Myeloma Treatment: The Promise of Novel Drug Classes
Jul 24, 2024
-Agonist.png "Toll-like Receptors Agonist")
Newsletter/Whitepaper